news
company Announcements
Case Study: Integra Healthcare in the Cayman Islands
Attomarker has partnered with Integra Healthcare in the Cayman Islands, where only 31% of the population has received a boosterdose. The medical team introduced the test to the community with a VIP launch and an informative in-depth article in the Cayman Compass,...
Attomarker Technology Overview
Attomarker technology is a label-free particle plasmon resonance multiplexed array that can measure the concentration quantitatively for up to 20 species in 10 µL blood sample in 7 minutes. The original idea came from a...
COVID-19 Antibody Immunity Test
The Attomarker Antibody Immunity Test measures antibodies in the blood to the SARS-CoV-2 coronavirus causing COVID-19. The total IgG response is measured to three antigens on the surface of the virus: Nucleocapsid (N),...
Were White House COVID victims lulled into false sense of security by current antigen tests?
Last week’s announcement that the most powerful man in the world had contracted COVID-19 calls into question the effectiveness of the White House testing regime.Screening with a test upon entry to the Rose Garden ‘super-spreader’ event on Sep 26th was clearly used as...
Hunting down the virus in the community will help resolve lab-based logjams and avoid lockdowns
The UK’s COVID-19 testing capacity has grown enormously over the past few months, but recent demand has grown even faster. The news is full of complaints about distant appointment offers and delays in getting results, so much so that the DHSC is now being forced to...
Is Attomarker’s Triple Antibody Test for COVID-19 now the best by far?
A recent Guardian article from Birmingham University biostatistics Professor John Deeks -https://bit.ly/34X9e9r - warned against cutting scientific corners in the pursuit of the ultimate COVID-19 antibody test. It had become apparent that the ‘98% sensitivity’...
Professor Andrew Shaw interviewed on television about Attomarker’s Triple Antibody Test
Attomarker’s Triple Antibody Test for COVID-19 authorised by the MHRA following positive trial results at St Thomas’ London
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Attomarker’s next-generation Triple Antibody Test for use in the UKThe Attomarker test detects antibodies to three different COVID-19 proteins in seven...
Attomarker’s rapid antibody technology has shown promising results in understanding COVID-19 in tests at St Thomas’ Hospital, London
Testing for COVID-19 currently relies on detecting virus RNA in a swab sample from the patient’s throat or nose. Laboratory analysis tells you if you have the virus where you were swabbed. It does not tell you if you have the...
COVID-19 – Attomarker technology currently being tested at St Thomas’s Hospital, London
Attomarker is supporting Professor Andrew Shaw’s research group at the University of Exeter in a series of important experiments to understand patient responses to the covid-19 coronavirus. Attomarker technology will allow...
